What PRF Technologies does

PRF Technologies Ltd. (NASDAQ: PRFX), formerly PainReform Ltd., is an Israel-based, publicly traded diversified company operating two distinct platforms: specialty pharmaceutical drug-delivery therapies and AI-driven solar asset analytics. The company rebranded from PainReform in January 2026 following shareholder approval to reflect its strategic expansion. The pharmaceutical portfolio is anchored by PRF-110, a proprietary oil-based extended-release formulation of ropivacaine designed to be deposited directly into the surgical wound bed to provide sustained 72-hour local analgesia with a single intraoperative administration, and OcuRing-K, a patent-protected bio-erodible sustained-release intraocular ring delivering ketorolac for post-cataract surgery inflammation control, developed through majority-owned subsidiary LayerBio, Inc. Both programs target the FDA 505(b)(2) regulatory pathway.

The AI platform comprises DeepSolar, an AI-driven SaaS for utility-scale solar plants that combines production forecasting, storage optimization, imbalance risk management, and real-time market decision support using plant-level operational data and localized weather modeling; DeepSolar Predict, a next-generation revenue optimization module extending coverage to wind and battery storage assets; and Smart TDD, an analytics-driven technical due diligence service for solar asset lifecycle events. DeepSolar is an active participant in the NVIDIA Connect Program and has a pending patent application for solar plant micro-climate forecast modeling. Pharmaceutical products remain pre-commercial pending FDA approvals; the FDA cleared the IND for OcuRing-K Phase II in April 2026, and PRF-110 reported positive preclinical head-to-head data versus ZYNRELEF in May 2026.

The company monetizes the solar platform through annual SaaS subscriptions for DeepSolar, one-time professional services fees for Smart TDD engagements, and a channel partnership with Blade Ranger Ltd. targeting 150MW+ enterprise portfolios. Named commercial deployments include SaaS agreements with Shikun & Binui Energy (71 MW Satu Mare, Romania) and Econergy (92 MW Romania pilot), plus a Smart TDD engagement with EDF Power Solutions Israel. As of December 31, 2025, PRF Technologies held approximately $4.1M in cash, cash equivalents, short-term deposits and restricted cash against a FY2025 net loss of $4.8M (improved from $14.6M in FY2024), positive working capital of approximately $2.0M, and completed approximately $4.0M in ATM equity issuances during 2025. No revenue is disclosed. The company is headquartered in Tel Aviv with an investor relations office in New York and an R&D presence in Boston via LayerBio.

Name

PRF Technologies

Legal name

PRF Technologies Ltd.

Website

https://prf-tech.com

Company type

Public

Founded year

2026

Operating status

Operating

Short description

PRF Technologies (NASDAQ: PRFX) is an Israel-based diversified company developing specialty pharmaceutical drug-delivery therapies (PRF-110, OcuRing-K via LayerBio) and AI-driven SaaS for utility-scale solar asset analytics (DeepSolar). Pharmaceutical programs remain pre-commercial; DeepSolar generates early enterprise SaaS revenue.

Ownership category

akta.pro rank

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. DeepSolar SaaS Subscriptions: SaaS subscription model for AI-driven solar analytics platform. Customers pay recurring subscription fees for access to DeepSolar platform providing continuous analytics, performance monitoring, and operational insights for solar assets.
2. Solar Technical Due Diligence Services: One-time service fees for technical due diligence engagements including commissioning verification, warranty expiry assessments, underperformance diagnostics, and asset acquisition due diligence using Smart TDD analytics.
3. Pharmaceutical Product Sales (Future): Revenue from sale of FDA-approved pharmaceutical products including PRF-110 for post-operative pain and OcuRing-K for cataract surgery. Products will be marketed through healthcare providers upon regulatory approval via 505(b)(2) pathway.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

PRF Technologies develops proprietary extended-release drug-delivery platforms for specialty pharmaceuticals—PRF-110, an oil-based ropivacaine formulation for post-operative analgesia, and OcuRing-K, a bio-erodible intraocular ring for cataract surgery—and operates DeepSolar, an AI-driven SaaS platform providing forecasting, diagnostics, storage optimization, and technical due diligence for utility-scale solar assets.

Product overview

PRF Technologies is a diversified innovation company operating two distinct platforms: specialty pharmaceutical therapies and AI-driven energy analytics. The pharmaceutical portfolio includes PRF-110 (oil-based extended-release local anesthetic for post-operative pain) and OcuRing-K (bio-erodible intraocular ring for sustained drug release during cataract surgery, developed through majority-owned subsidiary LayerBio). The AI platform includes DeepSolar (AI-driven solar asset analytics and optimization SaaS), DeepSolar Predict (revenue optimization for renewable energy assets), and Smart TDD (solar technical due diligence service). The company was rebranded from PainReform to PRF Technologies in January 2026 to reflect this diversified strategy.

Differentiator

Problem solved

Functional benefit

Brands

• PRF-110: Oil-based, viscous clear solution deposited directly into surgical wound bed for localized and extended post-operative analgesia. Based on the local anesthetic ropivacaine.
• OcuRing
• DeepSolar
• DeepSolar Predict
• Smart TDD

Products and services

• PRF-110 Oil-based, viscous, clear extended-release formulation of ropivacaine deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. Designed for prolonged local analgesia following surgery through a single administration.
• OcuRing-K (OcuRingTD) Bio-erodible polymer-based sustained-release intraocular ring applied to the haptic of an intraocular lens for use in cataract surgery. Delivers ketorolac (NSAID) through a single intraoperative application, eliminating the need for post-surgical eye drops. Developed through majority-owned subsidiary LayerBio, Inc.
• DeepSolar AI-driven SaaS platform for utility-scale solar assets providing advanced forecasting, diagnostics, and data-driven operational insights. Combines localized weather intelligence, production forecasting, imbalance risk management, storage optimization, and real-time market decision support for solar plant operators.
• Smart TDD (Smart Technical Due Diligence) Analytics-driven solar Technical Due Diligence service providing complete data coverage, advanced diagnostics, and rapid turnaround for investors, operators, insurers, and lenders at major asset lifecycle milestones including commissioning verification, warranty expiry checks, underperformance diagnosis, and asset acquisition support.

Quantifiable outcome

• Sustained 72-hour analgesic activity comparable to approved ZYNRELEF benchmark in head-to-head preclinical study
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core, strategic and minor.

• Blade Ranger Ltd.coreGTM or Marketing Partner · 17 March 2026Commercial collaboration agreement designed to accelerate DeepSolar AI-driven solar asset optimization platform expansion across utility-scale solar portfolios. Targets multiple large-scale commercial engagements, each with minimum scope of 150 megawatts. Blade Ranger operates at intersection of renewable energy development, asset optimization, and infrastructure advisory working with solar developers, IPPs, institutional investors, and large-scale asset owners.
• EDF Power Solutions IsraelcoreTechnology or Integration · 18 February 2026Commercial due diligence engagement for operational utility-scale solar plant in Israel. DeepSolar applies Smart TDD analytics to support structured independent technical review of solar asset condition and performance. EDF Group (Electricite De France) is one of the largest international energy companies and global leader in renewable energy.
• Shikun & Binui EnergycoreTechnology or Integration · 11 February 2026SaaS agreement for deployment of DeepSolar analytics platform at 71 MW Satu Mare photovoltaic site in Romania. DeepSolar provides continuous analytics and performance monitoring to enhance operational visibility and support data-driven asset management throughout the project's operating life.
• LayerBio, Inc.coreStrategic or Co-development Partner · 1 August 2025Majority investment acquired in August 2025. Boston-based company focused on ocular drug delivery. LayerBio develops OcuRing-K bio-erodible sustained-release intraocular ring for cataract surgery. PRF acquired LayerBio to expand pipeline and create synergies with clinical development activities.
• DeepSolarcoreStrategic or Co-development Partner · 1 March 2025Strategic acquisition completed in March 2025 expanding PRF into AI-driven solar analytics and establishing second high-growth operating platform. AI-driven solar analytics platform for utility-scale renewable energy assets.
• NVIDIA Connect ProgramstrategicTechnology or Integration · 1 January 2025DeepSolar is an active participant in the NVIDIA Connect Program supporting continued innovation in AI-powered renewable energy solutions. Program participation supports development of DeepSolar Predict AI-driven revenue optimization platform.
• Crescendo Communications, LLCminorOthersInvestor relations partner based in New York providing IR services for PRF Technologies. Located at 12 E. 49th Street, 18th Floor, New York, NY 10017.

Scale indicators7 records

Recent moves7 records

Expansion highlights8 records

Direct peers

• Heron Therapeutics: Heron markets ZYNRELEF, the approved extended-release post-operative local anesthetic that PRF-110 is being benchmarked against in preclinical studies. Head-to-head competitor in the same surgical pain therapeutic category with the same ropivacaine/bupivacaine mechanism class.
• Solargis: Solargis provides high-resolution solar resource data, forecasting, and bankability datasets for utility-scale solar projects. Comparable to DeepSolar's localized weather intelligence and micro-climate forecast modeling capabilities.
• AlsoEnergy: AlsoEnergy provides asset performance monitoring, forecasting, and controls software for utility-scale solar and storage portfolios. Direct competitor to DeepSolar in the operational analytics and forecasting layer for renewable energy assets.
• Aurora Solar: Aurora Solar is a leading SaaS platform for solar design, sales, and asset performance analytics. Comparable to DeepSolar as an AI-driven software platform serving utility and commercial-scale solar operators, though Aurora is more design-focused.
• EyePoint Pharmaceuticals: EyePoint develops sustained-release ocular drug delivery technologies (DURYSTA, bioerodible implants) for retinal and ophthalmic indications. Directly comparable to LayerBio's OcuRing platform in technology approach and end-market focus.
• Ocular Therapeutix: Ocular Therapeutix develops sustained-release ophthalmic drug delivery platforms (including bioerodible hydrogel-based products) targeting post-cataract surgery and other ocular indications. Closely comparable to PRF's OcuRing-K bio-erodible intraocular ring for cataract surgery.
• Pacira BioSciences: Pacira is the leader in sustained-release local anesthetic therapeutics (EXPAREL, bupivacaine liposome). It competes with PRF Technologies in the post-operative pain space and validates the commercial model of extended-release injectables for surgical sites.

Broad incumbents

• Tigo Energy: Tigo Energy offers module-level power electronics and solar optimization hardware with accompanying monitoring/analytics software. Adjacent incumbent in solar optimization and asset performance, with broader hardware-based offering than DeepSolar's pure software stack.

Regional players

• Inseego Corp: Inseego provides IoT and SaaS-based asset monitoring and analytics for industrial/energy customers. Comparable SaaS analytics business model to DeepSolar, though with a broader industrial vertical focus rather than solar-specific.

Emerging players

• Stem Inc: Stem applies AI-driven optimization to battery energy storage and renewable assets, similar to DeepSolar Predict's storage intelligence and revenue optimization modules. Comparable AI-for-renewables business model targeting similar enterprise buyers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PRF Technologies